Unlocking the "Code" of Patient Value, Menarini Shines at the 2024 SIP Expo
2024-08-14
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
From August 9 to 13, 2024, the highly anticipated SIP Conference was grandly opened in Hainan. The theme of this conference was "Moving Forward Under Pressure - Breaking Through and Reshaping from Stock to Increment", aiming to explore how companies can find opportunities in the challenges of weak industry growth and plan future development blueprints and strategic layouts. Menarini China CEO Chen Jialin was invited to attend and, together with many industry guests, unveiled the SIP Conference and delivered a keynote speech on "Enhancing Patient Value", explaining how prescription drug companies can innovate and change under the heavy pressure of the current development of the pharmaceutical industry, empower patients with effective solutions, and promote sustainable growth and transformation and upgrading of the industry.
Menarini China CEO Chen Jialin was invited to open the Xipu event
Chen Jialin said: "Menarini entered China in 2013 and witnessed the era of rapid development and change in the domestic pharmaceutical field. We are honored to be part of it. After more than ten years of deep cultivation in the health industry, Menarini has always been committed to using a diversified product portfolio and full marketing channels as a matrix to actively expand in-depth collaboration with all parties in the industry, provide Chinese users with healthy, efficient and convenient products and services, empower Chinese patients and consumers in all aspects, and promote the development of related diagnosis and treatment fields."
Menarini China CEO Chen Jialin delivered a keynote speech
At the "See the Future • Improve Patient Value" Health Industry Ecosystem Conference on the second day of the conference, Chen Jialin delivered a keynote speech entitled "Insight into Patient Needs, Create a New Ecosystem with Value". He explained the new landscape of the pharmaceutical industry from two perspectives: market changes leading the future development of prescription drugs, and prescription drug companies providing solutions for improving patient value. Menarini's male health field is a core business area with a complete product portfolio. In the long-term commercialization process, it has formed a deep market insight, accumulated mature clinical application experience and comprehensive solutions, and continued to improve the patient value of men's products through diversified channels.
Menarini supports the China Primary Health Care Foundation's Men's Health Charity Fund, releases the industry's first public welfare, authoritative professional popular science content "Men's Health and Partner Happiness Handbook", and launches the "Let Love Be Freer" sexual happiness self-test applet. Integrating erectile dysfunction (ED) and premature ejaculation (PE), the three major treatment concepts of "co-treatment of co-morbidity", "co-treatment of men and women", and "co-treatment of body and mind" proposed by the industry, provides multi-dimensional testing and guidance, covering lifestyle, psychology, co-morbidity and partner factors, etc., to help popularize scientific knowledge of men's health and provide clinical reference for standardized diagnosis and treatment of diseases.
Improving patient value is closely related to the convenience of medication. Based on the Chinese market, Menarini has built a multi-channel advantage of "hospitals, pharmacies, and e-commerce", and through an online and offline retail closed loop, it has comprehensively improved the accessibility of patients to high-quality innovative drugs. Menarini has cultivated retail channels and launched the "Love Life-Big Retail Men's Health Care Plan" by working with major chain stores and health partners. It focuses on the unmet needs of patients, the entire process of disease management for patients and their partners, and provides comprehensive care services to improve the current status of diagnosis and treatment of men's health diseases in China, improve the standardization of diagnosis and treatment, and help realize the grand blueprint of improving people's physical and mental health and overall quality of life.
Based on a series of efforts and achievements in continuously improving patient value in the field of men's health, Menarini's men's health product Cialis® was listed in the "2024 Health Industry Brand List" and was awarded the industry's highest honor, the "SIP Gold Award".
Menarini's men's health product Cialis® won the industry's highest honor "Cip Gold Award"
Chen Jialin pointed out: "As a multinational pharmaceutical company with a long-term diversified product portfolio, Menarini has a deep understanding of the pain points and difficulties of patient value, and continues to explore multiple solutions to improve it. In the face of the current pressures and challenges in the pharmaceutical industry, Menarini continues to think about and practice comprehensive health solutions to provide stronger support for patients. Starting from the actual needs of patients, we promote the enhancement and improvement of patient value in multiple dimensions, focusing not only on the effectiveness of treatment, but also on the diagnosis and treatment experience and quality of life of patients, providing more comprehensive, convenient and efficient health services."
About Menarini China
Menarini China is part of the Menarini Group, the world's largest Italian biopharmaceutical company with nearly 140 years of history and more than 17,000 employees in more than 140 countries. As one of the fastest growing markets for the Group's business, Menarini China's operations cover the entire commercial value chain from clinical research and development, registration and approval, and listing to life cycle management. We combine global and regional resource advantages with local customer insights to bring outstanding medical innovations to healthcare providers such as hospitals and create a healthy life for Chinese patients and consumers. We have a professional team of more than 700 employees, operating a diversified product portfolio in key therapeutic areas such as men's health, anti-allergy, medical beauty, digestion, consumer health, endocrinology, etc., including own brands and partner brands from the world's leading biotechnology companies.
